# ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC

Source: https://onco.cc/trials/nct01774721/  
OnCo record `nct01774721` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dacomitinib and Gefitinib in Non-small-cell lung cancer, run by Pfizer, completed.

## Summary

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC is a phase 3 interventional study registered as NCT01774721 by Pfizer, with 452 participants recorded, started 2013-05-09 and reaching its primary completion in 2016-07-29. Interventions recorded: Dacomitinib (PF-00299804), Gefitinib. Conditions recorded: Non-small Cell Lung Cancer With EGFR-Activating Mutations.

Linked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01774721
- Phase: 3
- Setting: ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S)
- Sponsor: Pfizer
- Enrolled: 452

## Sources

- ClinicalTrials.gov NCT01774721: https://clinicaltrials.gov/study/NCT01774721

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Dacomitinib](https://onco.cc/drugs/dacomitinib/), [Gefitinib](https://onco.cc/drugs/gefitinib/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct01774721.json